This company has been acquired
Chembio Diagnostics Crecimiento futuro
Future controles de criterios 0/6
Información clave
n/a
Tasa de crecimiento de los beneficios
n/a
Tasa de crecimiento del BPA
| Crecimiento de los beneficios de Medical Equipment | 16.4% |
| Tasa de crecimiento de los ingresos | n/a |
| Rentabilidad financiera futura | n/a |
| Cobertura de analistas | None |
| Última actualización | n/a |
Actualizaciones recientes sobre el crecimiento futuro
Recent updates
Chembio gets $3.2M contract from CDC to develop rapid test for syphilis
Sep 06Chembio stock rises 13% amid plans to develop rapid test for monkeypox
Aug 16Is Chembio Diagnostics (NASDAQ:CEMI) Using Debt In A Risky Way?
Nov 30
Analysts' Revenue Estimates For Chembio Diagnostics, Inc. (NASDAQ:CEMI) Are Surging Higher
Aug 08Does Chembio Diagnostics (NASDAQ:CEMI) Have A Healthy Balance Sheet?
Jul 22Chembio Diagnostics EPS beats by $0.10, beats on revenue
May 06Is Chembio Diagnostics (NASDAQ:CEMI) Using Debt Sensibly?
Apr 07Is Chembio Diagnostics, Inc.'s (NASDAQ:CEMI) Shareholder Ownership Skewed Towards Insiders?
Jan 16Chembio stock gains after COVID-19 tests nab European Union nod
Jan 14Is Chembio Diagnostics (NASDAQ:CEMI) Weighed On By Its Debt Load?
Dec 12
Chembio slumps 13% on delay of U.S. nod for coronavirus antibody test
Dec 04Chembio nabs BARDA contract for rapid respiratory antigen panel test
Dec 02En esta sección solemos presentar previsiones de crecimiento de ingresos y beneficios basadas en las estimaciones por consenso de analistas profesionales para ayudar a los inversores a comprender la capacidad de la empresa para generar beneficios. Pero como Chembio Diagnostics no ha proporcionado suficientes datos anteriores y no dispone de previsiones de analistas, sus beneficios futuros no pueden calcularse de forma fiable extrapolando datos anteriores o utilizando las previsiones de los analistas.
Es una situación poco común, ya que el 97% de las empresas disponibles en SimplyWall St sí disponen de datos financieros anteriores.
Previsiones de crecimiento de beneficios e ingresos
| Fecha | Ingresos | Beneficios | Flujo de caja libre | Flujo de caja operativo | Núm. de analistas medio |
|---|---|---|---|---|---|
| 12/31/2022 | 50 | -23 | -14 | -13 | N/A |
| 9/30/2022 | 60 | -36 | -19 | -17 | N/A |
| 6/30/2022 | 61 | -36 | -21 | -20 | N/A |
| 3/31/2022 | 58 | -38 | -29 | -28 | N/A |
| 12/31/2021 | 48 | -34 | -33 | -31 | N/A |
| 9/30/2021 | 37 | -27 | -31 | -29 | N/A |
| 6/30/2021 | 36 | -26 | -30 | -27 | N/A |
| 3/31/2021 | 34 | -25 | -25 | -20 | N/A |
| 12/31/2020 | 32 | -26 | -23 | -19 | N/A |
| 9/30/2020 | 29 | -22 | -21 | -17 | N/A |
| 6/30/2020 | 28 | -21 | -14 | -9 | N/A |
| 3/31/2020 | 33 | -16 | -14 | -10 | N/A |
| 12/31/2019 | 34 | -14 | -13 | -9 | N/A |
| 9/30/2019 | 35 | -13 | -15 | -11 | N/A |
| 6/30/2019 | 37 | -11 | -16 | -14 | N/A |
| 3/31/2019 | 35 | -10 | -16 | -14 | N/A |
| 12/31/2018 | 35 | -8 | -13 | -12 | N/A |
| 9/30/2018 | 33 | -7 | -6 | -5 | N/A |
| 6/30/2018 | 30 | -5 | -5 | -5 | N/A |
| 3/31/2018 | 25 | -5 | -4 | -3 | N/A |
| 12/31/2017 | 24 | -6 | -6 | -5 | N/A |
| 9/30/2017 | 22 | -7 | -9 | -8 | N/A |
| 6/30/2017 | 18 | -8 | -9 | -8 | N/A |
| 3/31/2017 | 18 | -15 | -8 | -8 | N/A |
| 12/31/2016 | 18 | -13 | -7 | -7 | N/A |
| 9/30/2016 | 18 | -11 | N/A | -1 | N/A |
| 6/30/2016 | 21 | -10 | N/A | 0 | N/A |
Previsiones de crecimiento futuro de los analistas
Ingresos vs. Tasa de ahorro: Insufficient data to determine if CEMI's forecast earnings growth is above the savings rate (2.1%).
Beneficios vs. Mercado: Insufficient data to determine if CEMI's earnings are forecast to grow faster than the US market
Beneficios de alto crecimiento: Insufficient data to determine if CEMI's earnings are expected to grow significantly over the next 3 years.
Ingresos vs. Mercado: Insufficient data to determine if CEMI's revenue is forecast to grow faster than the US market.
Ingresos de alto crecimiento: Insufficient data to determine if CEMI's revenue is forecast to grow faster than 20% per year.
Previsiones de crecimiento de los beneficios por acción
Rentabilidad financiera futura
ROE futura: Insufficient data to determine if CEMI's Return on Equity is forecast to be high in 3 years time